Chinese Herbs and Repurposing Old Drugs as Therapeutic Agents in the Regulation of Oxidative Stress and Inflammation in Pulmonary Diseases

References

• McGuinness AJ, Sapey E. Oxidative stress in COPD: sources, markers, and potential mechanisms. J Clin Med. 2017;6(2):21. doi:10.3390/jcm6020021
   PubMed Web of Science ®Google Scholar
• Qu J, Li Y, Zhong W, Gao P, Hu C. Recent developments in the role of reactive oxygen species in allergic asthma. J Thorac Dis. 2017;9(1):E32–e43. doi:10.21037/jtd.2017.01.05
   PubMed Web of Science ®Google Scholar
• Park HS, Kim SR, Lee YC. Impact of oxidative stress on lung diseases. Respirology. 2009;14(1):27–38. doi:10.1111/j.1440-1843.2008.01447.x
   PubMed Web of Science ®Google Scholar
• Cheng SE, Luo SF, Jou MJ, et al. Cigarette smoke extract induces cytosolic phospholipase A2 expression via NADPH oxidase, MAPKs, AP-1, and NF-κB in human tracheal smooth muscle cells. Free Radic Biol Med. 2009;46(7):948–960. doi:10.1016/j.freeradbiomed.2009.01.006
   PubMed Web of Science ®Google Scholar
• Cho RL, Yang CC, Lee IT, et al. Lipopolysaccharide induces ICAM-1 expression via a c-Src/NADPH oxidase/ROS-dependent NF-κB pathway in human pulmonary alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016;310(7):L639–657. doi:10.1152/ajplung.00109.2014
   PubMed Web of Science ®Google Scholar
• Hsu CK, Lee IT, Lin CC, Hsiao LD, Yang CM. Nox2/ROS-dependent human antigen R translocation contributes to TNF-α-induced SOCS-3 expression in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2014;306(6):L521–533. doi:10.1152/ajplung.00274.2013
   PubMed Web of Science ®Google Scholar
• Lee CW, Lin CC, Lee IT, Lee HC, Yang CM. Activation and induction of cytosolic phospholipase A2 by TNF-α mediated through Nox2, MAPKs, NF-κB, and p300 in human tracheal smooth muscle cells. J Cell Physiol. 2011;226(8):2103–2114. doi:10.1002/jcp.22537
   PubMed Web of Science ®Google Scholar
• Lin CC, Lin WN, Cho RL, Wang CY, Hsiao LD, Yang CM. TNF-α-induced cPLA2 expression via NADPH oxidase/reactive oxygen species-dependent NF-κB cascade on human pulmonary alveolar epithelial cells. Front Pharmacol. 2016;7:447.
   PubMed Web of Science ®Google Scholar
• Luo SF, Chang CC, Lee IT, et al. Activation of ROS/NF-κB and Ca2+/CaM kinase II are necessary for VCAM-1 induction in IL-1β-treated human tracheal smooth muscle cells. Toxicol Appl Pharmacol. 2009;237(1):8–21. doi:10.1016/j.taap.2009.02.025
   PubMed Web of Science ®Google Scholar
• Vallyathan V, Shi X. The role of oxygen free radicals in occupational and environmental lung diseases. Environ Health Perspect. 1997;105(Suppl 1):165–177. doi:10.1289/ehp.97105s1165
   PubMedGoogle Scholar
• Antus B, Kardos Z. Oxidative stress in COPD: molecular background and clinical monitoring. Curr Med Chem. 2015;22(5):627–650. doi:10.2174/092986732205150112104411
   PubMed Web of Science ®Google Scholar
• Liu Z, Ren Z, Zhang J, et al. Role of ROS and nutritional antioxidants in human diseases. Front Physiol. 2018;9:477. doi:10.3389/fphys.2018.00477
   PubMed Web of Science ®Google Scholar
• Lee I-T, Yang C-M. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochem Pharmacol. 2012;84(5):581–590. doi:10.1016/j.bcp.2012.05.005
   PubMed Web of Science ®Google Scholar
• Stewart RM, Weir EK, Montgomery MR, Niewoehner DE. Hydrogen peroxide contracts airway smooth muscle: a possible endogenous mechanism. Respir Physiol. 1981;45(3):333–342. doi:10.1016/0034-5687(81)90016-5
   PubMedGoogle Scholar
• Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol. 2006;533(1–3):222–239. doi:10.1016/j.ejphar.2005.12.087
   PubMed Web of Science ®Google Scholar
• Haddad JJ, Safieh-Garabedian B, Saadé NE, Kanaan SA, Land SC. Chemioxyexcitation (ΔpO2/ROS)-dependent release of IL-1β, IL-6 and TNF-α: evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium. Cytokine. 2001;13(3):138–147. doi:10.1006/cyto.2000.0789
   PubMed Web of Science ®Google Scholar
• Lee I-T, Yang C-M. Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013;2013:1–12. doi:10.1155/2013/791231
   Web of Science ®Google Scholar
• Harju T, Soini Y, Pääkkö R, Kinnula VL. Up-regulation of heme oxygenase-I in alveolar macrophages of newly diagnosed asthmatics. Respir Med. 2002;96(6):418–423. doi:10.1053/rmed.2001.1283
   PubMed Web of Science ®Google Scholar
• Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86(2):583–650.
   PubMed Web of Science ®Google Scholar
• Primiano T, Kensler TW, Kuppusamy P, Zweier JL, Sutter TR. Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones. Carcinogenesis. 1996;17(11):2291–2296. doi:10.1093/carcin/17.11.2291
   PubMed Web of Science ®Google Scholar
• Ryter SW, Kim HP, Nakahira K, Zuckerbraun BS, Morse D, Choi AM. Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system. Antioxid Redox Signal. 2007;9(12):2157–2173. doi:10.1089/ars.2007.1811
   PubMed Web of Science ®Google Scholar
• Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol. 2008;121(4):893–902.e892. doi:10.1016/j.jaci.2008.02.004
   Web of Science ®Google Scholar
• Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J. 2008;31(1):62–69. doi:10.1183/09031936.00036707
   PubMed Web of Science ®Google Scholar
• Gerthoffer WT, Singer CA. MAPK regulation of gene expression in airway smooth muscle. Respir Physiol Neurobiol. 2003;137(2–3):237–250. doi:10.1016/S1569-9048(03)00150-2
   PubMed Web of Science ®Google Scholar
• Mossman BT, Lounsbury KM, Reddy SP. Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am J Respir Cell Mol Biol. 2006;34(6):666–669. doi:10.1165/rcmb.2006-0047SF
   PubMed Web of Science ®Google Scholar
• Kumasawa F, Hashimoto S, Mizumura K, et al. Mitogen-activated protein kinase (MAPK) regulates leukotriene D4-induced HB-EGF and ADAM12 expression in human airway smooth muscle cells. Asian Pac J Allergy Immunol. 2013;31(1):58–66.
   PubMed Web of Science ®Google Scholar
• Pei YH, Cai XM, Chen J, et al. The role of p38 MAPK in acute paraquat-induced lung injury in rats. Inhal Toxicol. 2014;26(14):880–884. doi:10.3109/08958378.2014.970784
   PubMed Web of Science ®Google Scholar
• Madala SK, Schmidt S, Davidson C, Ikegami M, Wert S, Hardie WD. MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. Am J Respir Cell Mol Biol. 2012;46(3):380–388. doi:10.1165/rcmb.2011-0237OC
   PubMed Web of Science ®Google Scholar
• van der Velden JL, Ye Y, Nolin JD, et al. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin Transl Med. 2016;5(1):36. doi:10.1186/s40169-016-0117-2
   PubMedGoogle Scholar
• Lee I-T, Lee C-W, Tung W-H, et al. Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid–induced cPLA2/COX-2–dependent airway inflammatory responses. Am J Pathol. 2010;176(4):1671–1684. doi:10.2353/ajpath.2010.090714
   PubMed Web of Science ®Google Scholar
• Lin -C-C, Kuo C-T, Cheng C-Y, et al. IL-1β promotes A549 cell migration via MAPKs/AP-1-and NF-κB-dependent matrix metalloproteinase-9 expression. Cell Signal. 2009;21(11):1652–1662. doi:10.1016/j.cellsig.2009.07.002
   PubMed Web of Science ®Google Scholar
• Tzeng TF, Tzeng YC, Cheng YJ, Liou SS, Liu IM. The ethanol extract from lonicera japonica thunb. Regresses nonalcoholic steatohepatitis in a methionine- and choline-deficient diet-fed animal model. Nutrients. 2015;7(10):8670–8684. doi:10.3390/nu7105423
   PubMed Web of Science ®Google Scholar
• De Silva DS, Wilson RM, Hutchinson C, et al. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. Am J Physiol Heart Circ Physiol. 2009;296(6):H1983–1993. doi:10.1152/ajpheart.00002.2009
   PubMed Web of Science ®Google Scholar
• Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2012;27(2):341–350. doi:10.1111/j.1440-1746.2011.06939.x
   PubMed Web of Science ®Google Scholar
• Hou G, Yin Y, Han D, Wang QY, Kang J. Rosiglitazone attenuates the metalloprotease/anti-metalloprotease imbalance in emphysema induced by cigarette smoke: involvement of extracellular signal-regulated kinase and NF-κB signaling. Int J Chron Obstruct Pulmon Dis. 2015;10:715–724. doi:10.2147/COPD.S77514
   PubMed Web of Science ®Google Scholar
• Meng X, Sun X, Zhang Y, et al. PPARgamma agonist PGZ attenuates OVA-induced airway inflammation and airway remodeling via RGS4 signaling in mouse model. Inflammation. 2018;41(6):2079–2089. doi:10.1007/s10753-018-0851-2
   PubMed Web of Science ®Google Scholar
• Santos L, Rodrigues GB, Mota FVB, et al. New thiazolidinedione LPSF/GQ-2 inhibits NF-κB and MAPK activation in LPS-induced acute lung inflammation. Int Immunopharmacol. 2018;57:91–101. doi:10.1016/j.intimp.2018.02.011
   PubMed Web of Science ®Google Scholar
• Choi M, Rolle S, Rane M, Haller H, Luft FC, Kettritz R. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. 2003;63(1):96–106. doi:10.1046/j.1523-1755.2003.00718.x
   PubMed Web of Science ®Google Scholar
• Carlin CM, Peacock AJ, Welsh DJ. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. Am J Respir Cell Mol Biol. 2007;37(4):447–456. doi:10.1165/rcmb.2007-0012OC
   PubMed Web of Science ®Google Scholar
• Liu Q, Shi X, Tang L, et al. Salvianolic acid B attenuates experimental pulmonary inflammation by protecting endothelial cells against oxidative stress injury. Eur J Pharmacol. 2018;840:9–19. doi:10.1016/j.ejphar.2018.09.030
   PubMed Web of Science ®Google Scholar
• Lee JW, Park HA, Kwon OK, et al. Asiatic acid inhibits pulmonary inflammation induced by cigarette smoke. Int Immunopharmacol. 2016;39:208–217. doi:10.1016/j.intimp.2016.07.010
   PubMed Web of Science ®Google Scholar
• Jung HW, Chung YS, Kim YS, Park YK. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-κB in LPS-stimulated BV-2 microglial cells. Exp Mol Med. 2007;39(6):715–721. doi:10.1038/emm.2007.78
   PubMed Web of Science ®Google Scholar
• Ren Q, Guo F, Tao S, Huang R, Ma L, Fu P. Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-κB p65 and MAPK signaling pathways in septic AKI mice. Biomed Pharmacother. 2020;122:109772. doi:10.1016/j.biopha.2019.109772
   PubMed Web of Science ®Google Scholar
• Yang CC, Lin CC, Hsiao LD, Yang CM. Galangin inhibits thrombin-induced MMP-9 expression in SK-N-SH cells via protein kinase-dependent NF-κB phosphorylation. Int J Mol Sci. 2018;19(12):4084. doi:10.3390/ijms19124084
   PubMed Web of Science ®Google Scholar
• Qian J, Chen X, Chen X, et al. Kaempferol reduces K63-linked polyubiquitination to inhibit nuclear factor-κB and inflammatory responses in acute lung injury in mice. Toxicol Lett. 2019;306:53–60. doi:10.1016/j.toxlet.2019.02.005
   PubMed Web of Science ®Google Scholar
• Yu D, Li M, Tian Y, Liu J, Shang J. Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury. Life Sci. 2015;122:15–25. doi:10.1016/j.lfs.2014.11.014
   PubMed Web of Science ®Google Scholar
• Wang Q, Yao L, Xu K, et al. Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis. J Cell Mol Med. 2019;23(1):380–394. doi:10.1111/jcmm.13942
   PubMed Web of Science ®Google Scholar
• Tao J, Hou Y, Ma X, et al. An integrated global chemomics and system biology approach to analyze the mechanisms of the traditional Chinese medicinal preparation Eriobotrya japonica - Fritillaria usuriensis dropping pills for pulmonary diseases. BMC Complement Altern Med. 2016;16:4. doi:10.1186/s12906-015-0983-y
   PubMed Web of Science ®Google Scholar
• El-Agamy DS, El-Harbi KM, Khoshhal S, et al. Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways. Cancer Manag Res. 2019;11:47–61. doi:10.2147/CMAR.S186696
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. doi:10.1038/sigtrans.2017.23
   PubMed Web of Science ®Google Scholar
• Chow CW, Herrera Abreu MT, Suzuki T, Downey GP. Oxidative stress and acute lung injury. Am J Respir Cell Mol Biol. 2003;29(4):427–431. doi:10.1165/rcmb.F278
   PubMed Web of Science ®Google Scholar
• Xiao M, Zhu T, Zhang W, et al. Emodin ameliorates LPS-induced acute lung injury, involving the inactivation of NF-κB in mice. Int J Mol Sci. 2014;15(11):19355–19368. doi:10.3390/ijms151119355
   PubMed Web of Science ®Google Scholar
• Li N, Song Y, Zhao W, et al. Small interfering RNA targeting NF-κB attenuates lipopolysaccharide-induced acute lung injury in rats. BMC Physiol. 2016;16(1):7. doi:10.1186/s12899-016-0027-y
   PubMedGoogle Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.011
   PubMed Web of Science ®Google Scholar
• Zaynagetdinov R, Sherrill TP, Gleaves LA, et al. Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs. Oncotarget. 2016;7(5):5470–5482. doi:10.18632/oncotarget.6562
   PubMedGoogle Scholar
• Zhou L, Liu Y, Chen X, et al. Over-expression of nuclear factor-κB family genes and inflammatory molecules is related to chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:2131–2138. doi:10.2147/COPD.S164151
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD. Eur Respir J. 2002;20(3):556–563. doi:10.1183/09031936.02.00272002
   PubMed Web of Science ®Google Scholar
• Lee I-T, Luo S-F, Lee C-W, et al. Overexpression of HO-1 protects against TNF-α-mediated airway inflammation by down-regulation of TNFR1-dependent oxidative stress. Am J Pathol. 2009;175(2):519–532. doi:10.2353/ajpath.2009.090016
   PubMed Web of Science ®Google Scholar
• Schuliga M. NF-κB signaling in chronic inflammatory airway disease. Biomolecules. 2015;5(3):1266–1283. doi:10.3390/biom5031266
   PubMed Web of Science ®Google Scholar
• Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther. 2009;121(1):1–13. doi:10.1016/j.pharmthera.2008.09.003
   PubMed Web of Science ®Google Scholar
• Vesely PW, Staber PB, Hoefler G, Kenner L. Translational regulation mechanisms of AP-1 proteins. Mutat Res Rev Mutat Res. 2009;682(1):7–12. doi:10.1016/j.mrrev.2009.01.001
   Web of Science ®Google Scholar
• Karin M, Liu Z, Zandi E, et al. AP-‐1 function and regulation. Curr Opin Cell Biol. 1997;9(2):240–246. doi:10.1016/S0955-0674(97)80068-3
   PubMed Web of Science ®Google Scholar
• Wodrich W, Volm M. Overexpression of oncoproteins in non-small cell lung carcinomas of smokers. Carcinogenesis. 1993;14(6):1121–1124. doi:10.1093/carcin/14.6.1121
   PubMed Web of Science ®Google Scholar
• Guo RF, Lentsch AB, Sarma JV, et al. Activator protein-1 activation in acute lung injury. Am J Pathol. 2002;161(1):275–282. doi:10.1016/S0002-9440(10)64179-X
   PubMed Web of Science ®Google Scholar
• Haase M, Koslowski R, Lengnick A, et al. Cellular distribution of c-Jun and c-Fos in rat lung before and after bleomycin induced injury. Virchows Archiv. 1997;431(6):441–448. doi:10.1007/s004280050121
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock I. Transcription factors and asthma. Eur Respir J. 1998;12(1):221–234. doi:10.1183/09031936.98.12010221
   PubMed Web of Science ®Google Scholar
• Kips JC, Tavernier JH, Joos GF, Peleman RA, Pauwels RA. The potential role of tumour necrosis factor α in asthma. Clin Exp Allergy. 1993;23(4):247–250. doi:10.1111/j.1365-2222.1993.tb00317.x
   PubMed Web of Science ®Google Scholar
• Kersul AL, Iglesias A, Á R, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 2011;47(4):176–183. doi:10.1016/j.arbres.2010.12.003
   PubMed Web of Science ®Google Scholar
• Ying S, Robinson DS, Varney V, et al. TNF-α mRNA expression in allergic inflammation. Clin Exp Allergy. 1991;21(6):745–750. doi:10.1111/j.1365-2222.1991.tb03205.x
   PubMed Web of Science ®Google Scholar
• Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, −5, and −6 and tumor necrosis factor-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994;10(5):471–480. doi:10.1165/ajrcmb.10.5.8179909
   PubMed Web of Science ®Google Scholar
• Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 1995;152(1):76–80. doi:10.1164/ajrccm.152.1.7599866
   PubMed Web of Science ®Google Scholar
• Adner M, Rose AC, Zhang Y, et al. An assay to evaluate the long-term effects of inflammatory mediators on murine airway smooth muscle: evidence that TNFα up-regulates 5-HT2A-mediated contraction. Br J Pharmacol. 2002;137(7):971–982. doi:10.1038/sj.bjp.0704928
   PubMed Web of Science ®Google Scholar
• Huber M, Beutler B, Keppler D. Tumor necrosis factor α stimulates leukotriene production in vivo. Eur J Immunol. 1988;18(12):2085–2088. doi:10.1002/eji.1830181233
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699–1705. doi:10.1056/NEJMoa012705
   PubMed Web of Science ®Google Scholar
• Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis. 2002;2(3):171–179. doi:10.1016/S1473-3099(02)00226-8
   PubMed Web of Science ®Google Scholar
• Ellingsen E, Morath S, Flo T, et al. Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit. 2002;8(5):Br149–156.
   PubMed Web of Science ®Google Scholar
• Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem. 1969;244(23):6388–6394. doi:10.1016/S0021-9258(18)63477-5
   PubMed Web of Science ®Google Scholar
• Fredenburgh LE, Perrella MA, Mitsialis SA. The role of heme oxygenase-1 in pulmonary disease. Am J Respir Cell Mol Biol. 2007;36(2):158–165. doi:10.1165/rcmb.2006-0331TR
   PubMed Web of Science ®Google Scholar
• Horváth I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, Barnes PJ. Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax. 1998;53(8):668–672. doi:10.1136/thx.53.8.668
   PubMed Web of Science ®Google Scholar
• Almolki A, Taillé C, Martin GF, et al. Heme oxygenase attenuates allergen-induced airway inflammation and hyperreactivity in guinea pigs. Am J Physiol Lung Cell Mol Physiol. 2004;287(1):L26–34. doi:10.1152/ajplung.00237.2003
   PubMed Web of Science ®Google Scholar
• Wagener FA, Eggert A, Boerman OC, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood. 2001;98(6):1802–1811. doi:10.1182/blood.V98.6.1802
   PubMed Web of Science ®Google Scholar
• Yang CC, Hsiao LD, Lin HH, et al. Induction of HO-1 by 5, 8-dihydroxy-4ʹ,7-dimethoxyflavone via activation of ROS/p38 MAPK/Nrf2 attenuates thrombin-induced connective tissue growth factor expression in human cardiac fibroblasts. Oxid Med Cell Longev. 2020;2020:1080168. doi:10.1155/2020/1080168
   PubMed Web of Science ®Google Scholar
• Slebos DJ, Kerstjens HA, Rutgers SR, Kauffman HF, Choi AM, Postma DS. Haem oxygenase-1 expression is diminished in alveolar macrophages of patients with COPD. Eur Respir J. 2004;23(4):652–653;author reply 653. doi:10.1183/09031936.04.00127904
   PubMedGoogle Scholar
• Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med. 2004;37(8):1097–1104. doi:10.1016/j.freeradbiomed.2004.07.008
   PubMed Web of Science ®Google Scholar
• Even B, Fayad-Kobeissi S, Gagliolo JM, et al. Heme oxygenase-1 induction attenuates senescence in chronic obstructive pulmonary disease lung fibroblasts by protecting against mitochondria dysfunction. Aging Cell. 2018;17(6):e12837. doi:10.1111/acel.12837
   PubMed Web of Science ®Google Scholar
• Wei J, Fan G, Zhao H, Li J. Heme oxygenase-1 attenuates inflammation and oxidative damage in a rat model of smoke-induced emphysema. Int J Mol Med. 2015;36(5):1384–1392. doi:10.3892/ijmm.2015.2353
   PubMed Web of Science ®Google Scholar
• Chen Y, Yuan T, Zhang H, et al. Activation of Nrf2 attenuates pulmonary vascular remodeling via inhibiting endothelial-to-mesenchymal transition: an insight from a plant polyphenol. Int J Biol Sci. 2017;13(8):1067–1081. doi:10.7150/ijbs.20316
   PubMed Web of Science ®Google Scholar
• Divya T, Dineshbabu V, Soumyakrishnan S, Sureshkumar A, Sudhandiran G. Celastrol enhances Nrf2 mediated antioxidant enzymes and exhibits anti-fibrotic effect through regulation of collagen production against bleomycin-induced pulmonary fibrosis. Chem Biol Interact. 2016;246:52–62. doi:10.1016/j.cbi.2016.01.006
   PubMed Web of Science ®Google Scholar
• Hussain T, Al-Attas OS, Alamery S, Ahmed M, Odeibat HAM, Alrokayan S. The plant flavonoid, fisetin alleviates cigarette smoke-induced oxidative stress, and inflammation in Wistar rat lungs. J Food Biochem. 2019;43(8):e12962. doi:10.1111/jfbc.12962
   PubMed Web of Science ®Google Scholar
• Aladaileh SH, Abukhalil MH, Saghir SAM, et al. Galangin activates Nrf2 signaling and attenuates oxidative damage, inflammation, and apoptosis in a rat model of cyclophosphamide-induced hepatotoxicity. Biomolecules. 2019;9(8):346. doi:10.3390/biom9080346
   PubMed Web of Science ®Google Scholar
• Shu YS, Tao W, Miao QB, Lu SC, Zhu YB. Galangin dampens mice lipopolysaccharide-induced acute lung injury. Inflammation. 2014;37(5):1661–1668. doi:10.1007/s10753-014-9894-1
   PubMed Web of Science ®Google Scholar
• Gao SS, Choi BM, Chen XY, et al. Kaempferol suppresses cisplatin-induced apoptosis via inductions of heme oxygenase-1 and glutamate-cysteine ligase catalytic subunit in HEI-OC1 cell. Pharm Res. 2010;27(2):235–245.
   PubMed Web of Science ®Google Scholar
• Hong JT, Yen JH, Wang L, Lo YH, Chen ZT, Wu MJ. Regulation of heme oxygenase-1 expression and MAPK pathways in response to kaempferol and rhamnocitrin in PC12 cells. Toxicol Appl Pharmacol. 2009;237(1):59–68. doi:10.1016/j.taap.2009.02.014
   PubMed Web of Science ®Google Scholar
• Hirose E, Matsushima M, Takagi K, et al. Involvement of heme oxygenase-1 in kaempferol-induced anti-allergic actions in RBL-2H3 cells. Inflammation. 2009;32(2):99–108. doi:10.1007/s10753-009-9108-4
   PubMed Web of Science ®Google Scholar
• Yao H, Sun J, Wei J, Zhang X, Chen B, Lin Y. Kaempferol protects blood vessels from damage induced by oxidative stress and inflammation in association with the Nrf2/HO-1 signaling pathway. Front Pharmacol. 2020;11:1118. doi:10.3389/fphar.2020.01118
   PubMed Web of Science ®Google Scholar
• Sun GB, Sun X, Wang M, et al. Oxidative stress suppression by luteolin-induced heme oxygenase-1 expression. Toxicol Appl Pharmacol. 2012;265(2):229–240. doi:10.1016/j.taap.2012.10.002
   PubMed Web of Science ®Google Scholar
• Liu S, Li G, Tang H, et al. Madecassoside ameliorates lipopolysaccharide-induced neurotoxicity in rats by activating the Nrf2-HO-1 pathway. Neurosci Lett. 2019;709:134386. doi:10.1016/j.neulet.2019.134386
   PubMed Web of Science ®Google Scholar
• Wang W, Wu L, Li Q, et al. Madecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF-κB and activating Nrf2/HO-1 signaling. Biomed Pharmacother. 2018;103:1137–1145. doi:10.1016/j.biopha.2018.04.162
   PubMed Web of Science ®Google Scholar
• Reisman SA, Aleksunes LM, Klaassen CD. Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. Biochem Pharmacol. 2009;77(7):1273–1282. doi:10.1016/j.bcp.2008.12.028
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang P, Chen X, He G. PI3K and ERK/Nrf2 pathways are involved in oleanolic acid-induced heme oxygenase-1 expression in rat vascular smooth muscle cells. J Cell Biochem. 2011;112(6):1524–1531. doi:10.1002/jcb.23065
   PubMed Web of Science ®Google Scholar
• Chen RJ, Guo XY, Cheng BH, Gong YQ, Ying BY, Lin MX. Saikosaponin a inhibits cigarette smoke-induced oxidant stress and inflammatory responses by activation of Nrf2. Inflammation. 2018;41(4):1297–1303. doi:10.1007/s10753-018-0778-7
   PubMed Web of Science ®Google Scholar
• Liby K, Hock T, Yore MM, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005;65(11):4789–4798. doi:10.1158/0008-5472.CAN-04-4539
   PubMed Web of Science ®Google Scholar
• El-Agamy DS, Shaaban AA, Almaramhy HH, Elkablawy S, Elkablawy MA. Pristimerin as a novel hepatoprotective agent against experimental autoimmune hepatitis. Front Pharmacol. 2018;9:292. doi:10.3389/fphar.2018.00292
   PubMed Web of Science ®Google Scholar
• Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol. 2000;60(8):1121–1128. doi:10.1016/S0006-2952(00)00443-3
   PubMed Web of Science ®Google Scholar
• Alam J, Camhi S, Choi AM. Identification of a second region upstream of the mouse heme oxygenase-1 gene that functions as a basal level and inducer-dependent transcription enhancer. J Biol Chem. 1995;270(20):11977–11984. doi:10.1074/jbc.270.20.11977
   PubMed Web of Science ®Google Scholar
• Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol. 2003;43:233–260. doi:10.1146/annurev.pharmtox.43.100901.140229
   PubMed Web of Science ®Google Scholar
• Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116. doi:10.1146/annurev.pharmtox.46.120604.141046
   PubMed Web of Science ®Google Scholar
• Yamada N, Yamaya M, Okinaga S, et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000;66(1):187–195. doi:10.1086/302729
   PubMed Web of Science ®Google Scholar
• Pawlinski R, Tencati M, Hampton CR, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007;116(20):2298–2306. doi:10.1161/CIRCULATIONAHA.107.692764
   PubMed Web of Science ®Google Scholar
• Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation. 2004;110(10):1296–1302. doi:10.1161/01.CIR.0000140694.67251.9C
   PubMed Web of Science ®Google Scholar
• Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37(12):2064–2071. doi:10.1016/j.freeradbiomed.2004.09.009
   PubMed Web of Science ®Google Scholar
• Lin CC, Lin WN, Cho RL, et al. Induction of HO-1 by mevastatin mediated via a nox/ROS-dependent c-Src/PDGFRα/PI3K/Akt/Nrf2/ARE cascade suppresses TNF-α-induced lung inflammation. J Clin Med. 2020;9(1):226. doi:10.3390/jcm9010226
   PubMed Web of Science ®Google Scholar
• Yang CM, Lin CC, Yang CC, Cho RL, Hsiao LD. Mevastatin-induced AP-1-dependent HO-1 expression suppresses vascular cell adhesion molecule-1 expression and monocyte adhesion on human pulmonary alveolar epithelial cells challenged with TNF-α. Biomolecules. 2020;10(3):381. doi:10.3390/biom10030381
   PubMed Web of Science ®Google Scholar
• Lin CC, Hsiao LD, Cho RL, Yang CM. CO-releasing molecule-2 induces Nrf2/ARE-dependent heme oxygenase-1 expression suppressing TNF-α-induced pulmonary inflammation. J Clin Med. 2019;8(4).
   Web of Science ®Google Scholar
• Lin CC, Chiang YC, Cho RL, et al. Up-regulation of PYK2/PKCα-dependent haem oxygenase-1 by CO-releasing molecule-2 attenuates TNF-α-induced lung inflammation. Br J Pharmacol. 2018;175(3):456–468. doi:10.1111/bph.14094
   PubMed Web of Science ®Google Scholar
• Lin CC, Hsiao LD, Cho RL, Yang CM. Carbon monoxide releasing molecule-2-upregulated ROS-dependent heme oxygenase-1 axis suppresses lipopolysaccharide-induced airway inflammation. Int J Mol Sci. 2019;20(13):3157. doi:10.3390/ijms20133157
   PubMed Web of Science ®Google Scholar
• Yang CM, Lin CC, Lee IT, et al. c-Src-dependent transactivation of EGFR mediates CORM-2-induced HO-1 expression in human tracheal smooth muscle cells. J Cell Physiol. 2015;230(10):2351–2361. doi:10.1002/jcp.24912
   PubMed Web of Science ®Google Scholar
• Cheng SE, Lee IT, Lin CC, Kou YR, Yang CM. Cigarette smoke particle-phase extract induces HO-1 expression in human tracheal smooth muscle cells: role of the c-Src/NADPH oxidase/MAPK/Nrf2 signaling pathway. Free Radic Biol Med. 2010;48(10):1410–1422. doi:10.1016/j.freeradbiomed.2010.02.026
   PubMed Web of Science ®Google Scholar
• Chung JH, Seo AY, Chung SW, et al. Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res Rev. 2008;7(2):126–136. doi:10.1016/j.arr.2008.01.001
   PubMed Web of Science ®Google Scholar
• Makris D, Manoulakas E, Komnos A, et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med. 2011;39(11):2440–2446. doi:10.1097/CCM.0b013e318225742c
   PubMed Web of Science ®Google Scholar
• Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 2002;941(1–2):1–10. doi:10.1016/S0006-8993(02)02480-0
   PubMed Web of Science ®Google Scholar
• Cho RL, Yang CC, Tseng HC, Hsiao LD, Lin CC, Yang CM. Haem oxygenase-1 up-regulation by rosiglitazone via ROS-dependent Nrf2-antioxidant response elements axis or PPARγ attenuates LPS-mediated lung inflammation. Br J Pharmacol. 2018;175(20):3928–3946. doi:10.1111/bph.14465
   PubMed Web of Science ®Google Scholar
• Wang L, Waltenberger B, Pferschy-Wenzig EM, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 2014;92(1):73–89.
   PubMed Web of Science ®Google Scholar
• Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46(8):1319–1327. doi:10.2337/diab.46.8.1319
   PubMed Web of Science ®Google Scholar
• Seedorf U, Aberle J. Emerging roles of PPARδ in metabolism. Biochim Biophys Acta. 2007;1771(9):1125–1131. doi:10.1016/j.bbalip.2007.04.017
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci U S A. 1995;92(17):7921–7925. doi:10.1073/pnas.92.17.7921
   PubMed Web of Science ®Google Scholar
• Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). Differential activity of PPARγ-1 and −2 isoforms and influence of insulin. J Biol Chem. 1997;272(32):20230–20235. doi:10.1074/jbc.272.32.20230
   PubMed Web of Science ®Google Scholar
• Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99(10):2416–2422. doi:10.1172/JCI119424
   PubMed Web of Science ®Google Scholar
• Gearing KL, Göttlicher M, Teboul M, Widmark E, Gustafsson JA. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A. 1993;90(4):1440–1444. doi:10.1073/pnas.90.4.1440
   PubMed Web of Science ®Google Scholar
• Yu S, Reddy JK. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta. 2007;1771(8):936–951. doi:10.1016/j.bbalip.2007.01.008
   PubMed Web of Science ®Google Scholar
• Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54(8):2460–2470. doi:10.2337/diabetes.54.8.2460
   PubMed Web of Science ®Google Scholar
• Cho RL, Lin WN, Wang CY, et al. Heme oxygenase-1 induction by rosiglitazone via PKCα/AMPKα/p38 MAPKα/SIRT1/PPARγ pathway suppresses lipopolysaccharide-mediated pulmonary inflammation. Biochem Pharmacol. 2018;148:222–237. doi:10.1016/j.bcp.2017.12.024
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289. doi:10.1016/S0140-6736(05)67528-9
   PubMed Web of Science ®Google Scholar
• Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, The WW. PPARα-leukotriene B4 pathway to inflammation control. Nature. 1996;384(6604):39–43. doi:10.1038/384039a0
   PubMed Web of Science ®Google Scholar
• Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144–152. doi:10.1016/j.atherosclerosis.2017.03.032
   PubMed Web of Science ®Google Scholar
• Marfella R, D’Amico M, Esposito K, et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes. 2006;55(3):622–632. doi:10.2337/diabetes.55.03.06.db05-0832
   PubMed Web of Science ®Google Scholar
• Skochko OV, Kaidashev IP. Effect of pioglitazone on insulin resistance, progression of atherosclerosis and clinical course of coronary heart disease. Wiad Lek. 2017;70(5):881–890.
   PubMedGoogle Scholar
• van Wijk JP, Cabezas MC, Coll B, Joven J, Rabelink TJ, de Koning EJ. Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes. Atherosclerosis. 2006;186(1):152–159. doi:10.1016/j.atherosclerosis.2005.07.001
   PubMed Web of Science ®Google Scholar
• Werner C, Kamani CH, Gensch C, Böhm M, Laufs U. The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes. 2007;56(10):2609–2615. doi:10.2337/db07-0069
   PubMed Web of Science ®Google Scholar
• Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134(3):688–695. doi:10.1053/j.gastro.2007.12.012
   PubMed Web of Science ®Google Scholar
• Liang HL, Ouyang Q. [A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis]. Zhonghua Nei Ke Za Zhi. 2006;45(7):548–551. Chinese.
   PubMedGoogle Scholar
• Pedersen G, Brynskov J. Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-γ activity. Am J Gastroenterol. 2010;105(7):1595–1603. doi:10.1038/ajg.2009.749
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–1331. doi:10.1056/NEJMoa1506930
   PubMed Web of Science ®Google Scholar
• Marder W, Khalatbari S, Myles JD, et al. The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J Am Heart Assoc. 2013;2(6):e000441. doi:10.1161/JAHA.113.000441
   PubMed Web of Science ®Google Scholar
• Ormseth MJ, Oeser AM, Cunningham A, et al. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial. Arthritis Res Ther. 2013;15(5):R110. doi:10.1186/ar4290
   PubMed Web of Science ®Google Scholar
• Ormseth MJ, Oeser AM, Cunningham A, et al. Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy. Arthritis Rheumatol. 2014;66(9):2331–2338. doi:10.1002/art.38686
   PubMed Web of Science ®Google Scholar
• Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 2005;44(1):126–129. doi:10.1093/rheumatology/keh423
   PubMed Web of Science ®Google Scholar
• Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-γ inhibit keratinocyte proliferation. Arch Dermatol. 2000;136(5):609–616. doi:10.1001/archderm.136.5.609
   PubMed Web of Science ®Google Scholar
• Rinne ST, Liu CF, Feemster LC, et al. Thiazolidinediones are associated with a reduced risk of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2015;10:1591–1597. doi:10.2147/COPD.S82643
   PubMed Web of Science ®Google Scholar
• De Belilovsky C, Roo-Rodriguez E, Baudouin C, Menu F, Chadoutaud B, Msika P. Natural peroxisome proliferator-activated receptor-α agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis. J Dermatolog Treat. 2011;22(6):359–365. doi:10.3109/09546634.2010.499932
   PubMed Web of Science ®Google Scholar
• Fukaya M, Kimata H. Topical clofibrate improves symptoms in patients with atopic dermatitis and reduces serum TARC levels: a randomized, double-blind, placebo-controlled pilot study. J Drugs Dermatol. 2014;13(3):259–263.
   PubMed Web of Science ®Google Scholar
• Hammad H, de Heer HJ, Soullie T, et al. Activation of peroxisome proliferator-activated receptor-γ in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol. 2004;164(1):263–271. doi:10.1016/S0002-9440(10)63116-1
   PubMed Web of Science ®Google Scholar
• Kim SR, Lee KS, Park HS, et al. Involvement of IL-10 in peroxisome proliferator-activated receptor γ-mediated anti-inflammatory response in asthma. Mol Pharmacol. 2005;68(6):1568–1575. doi:10.1124/mol.105.017160
   PubMed Web of Science ®Google Scholar
• Lee HY, Rhee CK, Kang JY, et al. Effect of intranasal rosiglitazone on airway inflammation and remodeling in a murine model of chronic asthma. Korean J Intern Med. 2016;31(1):89–97. doi:10.3904/kjim.2016.31.1.89
   PubMed Web of Science ®Google Scholar
• Yin Y, Hou G, Li ER, Wang QY, Kang J. Regulation of cigarette smoke-induced toll-like receptor 4 expression by peroxisome proliferator-activated receptor-γ agonists in bronchial epithelial cells. Respirology. 2013;18(Suppl 3):30–39. doi:10.1111/resp.12167
   PubMedGoogle Scholar
• Liu DS, Liu WJ, Chen L, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates acrolein-induced airway mucus hypersecretion in rats. Toxicology. 2009;260(1–3):112–119. doi:10.1016/j.tox.2009.03.016
   PubMed Web of Science ®Google Scholar
• Rossi A, Inciardi RM, Rossi A, et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther. 2017;44:16–23. doi:10.1016/j.pupt.2017.03.001
   PubMed Web of Science ®Google Scholar
• Liu D, Zeng BX, Zhang SH, Yao SL. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res. 2005;54(11):464–470. doi:10.1007/s00011-005-1379-0
   PubMed Web of Science ®Google Scholar
• Neri T, Armani C, Pegoli A, et al. Role of NF-κB and PPAR-γ in lung inflammation induced by monocyte-derived microparticles. Eur Respir J. 2011;37(6):1494–1502. doi:10.1183/09031936.00023310
   PubMed Web of Science ®Google Scholar
• Momoi A, Murao K, Imachi H, et al. Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione. Chest. 2001;120(4):1293–1300. doi:10.1378/chest.120.4.1293
   PubMed Web of Science ®Google Scholar
• Cheng Y, Li S, Wang M, Cheng C, Liu R. Peroxisome proliferator activated receptor gamma (PPARγ) agonist rosiglitazone ameliorate airway inflammation by inhibiting toll-like receptor 2 (TLR2)/Nod-like receptor with pyrin domain containing 3 (NLRP3) inflammatory corpuscle activation in asthmatic mice. Med Sci Monit. 2018;24:9045–9053. doi:10.12659/MSM.910766
   PubMed Web of Science ®Google Scholar
• Mirakaj V, Mutz C, Vagts D, et al. Rosiglitazone dampens pulmonary inflammation in a porcine model of acute lung injury. Inflammation. 2014;37(4):1102–1110. doi:10.1007/s10753-014-9834-0
   PubMed Web of Science ®Google Scholar
• Birrell MA, Patel HJ, McCluskie K, et al. PPAR-γ agonists as therapy for diseases involving airway neutrophilia. Eur Respir J. 2004;24(1):18–23. doi:10.1183/09031936.04.00098303
   PubMed Web of Science ®Google Scholar
• Morissette MC, Shen P, Thayaparan D, Stämpfli MR. Impacts of peroxisome proliferator-activated receptor-γ activation on cigarette smoke-induced exacerbated response to bacteria. Eur Respir J. 2015;45(1):191–200. doi:10.1183/09031936.00004314
   PubMed Web of Science ®Google Scholar
• Lea S, Plumb J, Metcalfe H, et al. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. Eur Respir J. 2014;43(2):409–420. doi:10.1183/09031936.00187812
   PubMed Web of Science ®Google Scholar
• Gopal R, Mendy A, Marinelli MA, et al. Peroxisome proliferator-activated receptor gamma (PPARγ) suppresses inflammation and bacterial clearance during influenza-bacterial super-infection. Viruses. 2019;11(6). doi:10.3390/v11060505
   PubMed Web of Science ®Google Scholar
• Xu J, Zhu YT, Wang GZ, et al. The PPARgamma agonist, rosiglitazone, attenuates airway inflammation and remodeling via heme oxygenase-1 in murine model of asthma. Acta Pharmacol Sin. 2015;36(2):171–178. doi:10.1038/aps.2014.128
   PubMed Web of Science ®Google Scholar
• Kronke G, Kadl A, Ikonomu E, et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2007;27(6):1276–1282. doi:10.1161/ATVBAHA.107.142638
   PubMed Web of Science ®Google Scholar
• Kulkarni AA, Woeller CF, Thatcher TH, Ramon S, Phipps RP, Sime PJ. Emerging PPARγ-independent role of PPARγ ligands in lung diseases. PPAR Res. 2012;2012:705352. doi:10.1155/2012/705352
   PubMed Web of Science ®Google Scholar
• Kadam L, Gomez-Lopez N, Mial TN, Kohan-Ghadr HR, Drewlo S. Rosiglitazone regulates TLR4 and rescues HO-1 and NRF2 expression in myometrial and decidual macrophages in inflammation-induced preterm birth. Reprod Sci. 2017;24(12):1590–1599. doi:10.1177/1933719117697128
   PubMed Web of Science ®Google Scholar
• He J, Qi D, Tang XM, et al. Rosiglitazone promotes ENaC-mediated alveolar fluid clearance in acute lung injury through the PPARγ/SGK1 signaling pathway. Cell Mol Biol Lett. 2019;24:35. doi:10.1186/s11658-019-0154-0
   PubMed Web of Science ®Google Scholar
• Lin Q, Fang LP, Zhou WW, Liu XM. Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Exp Lung Res. 2010;36(2):120–128. doi:10.3109/01902140903214659
   PubMed Web of Science ®Google Scholar
• Jin GY, Bok SM, Han YM, et al. Effectiveness of rosiglitazone on bleomycin-induced lung fibrosis: assessed by micro-computed tomography and pathologic scores. Eur J Radiol. 2012;81(8):1901–1906. doi:10.1016/j.ejrad.2010.12.061
   PubMed Web of Science ®Google Scholar
• Ward JE, Fernandes DJ, Taylor CC, Bonacci JV, Quan L, Stewart AG. The PPARγ ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Pulm Pharmacol Ther. 2006;19(1):39–46. doi:10.1016/j.pupt.2005.02.005
   PubMed Web of Science ®Google Scholar
• Racanelli AC, Kikkers SA, Choi AMK, Cloonan SM. Autophagy and inflammation in chronic respiratory disease. Autophagy. 2018;14(2):221–232. doi:10.1080/15548627.2017.1389823
   PubMed Web of Science ®Google Scholar
• Chima RS, Hake PW, Piraino G, Mangeshkar P, Denenberg A, Zingarelli B. Ciglitazone ameliorates lung inflammation by modulating the inhibitor κB protein kinase/nuclear factor-κB pathway after hemorrhagic shock. Crit Care Med. 2008;36(10):2849–2857. doi:10.1097/CCM.0b013e318187810e
   PubMed Web of Science ®Google Scholar
• Aoki Y, Maeno T, Aoyagi K, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration. 2009;77(3):311–319. doi:10.1159/000168676
   PubMed Web of Science ®Google Scholar
• Milam JE, Keshamouni VG, Phan SH, et al. PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294(5):L891–901. doi:10.1152/ajplung.00333.2007
   PubMed Web of Science ®Google Scholar
• Jumeau C, Rupin A, Chieng-Yane P, et al. Direct thrombin inhibitors prevent left atrial remodeling associated with heart failure in rats. JACC Basic Transl Sci. 2016;1(5):328–339. doi:10.1016/j.jacbts.2016.05.002
   PubMedGoogle Scholar
• Ferguson HE, Thatcher TH, Olsen KC, et al. Peroxisome proliferator-activated receptor-γ ligands induce heme oxygenase-1 in lung fibroblasts by a PPARγ-independent, glutathione-dependent mechanism. Am J Physiol Lung Cell Mol Physiol. 2009;297(5):L912–919. doi:10.1152/ajplung.00148.2009
   PubMed Web of Science ®Google Scholar
• Reddy RC, Narala VR, Keshamouni VG, Milam JE, Newstead MW, Standiford TJ. Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-γ. Blood. 2008;112(10):4250–4258. doi:10.1182/blood-2007-12-128967
   PubMed Web of Science ®Google Scholar
• Wang AC, Dai X, Luu B, Conrad DJ. Peroxisome proliferator-activated receptor-γ regulates airway epithelial cell activation. Am J Respir Cell Mol Biol. 2001;24(6):688–693. doi:10.1165/ajrcmb.24.6.4376
   PubMed Web of Science ®Google Scholar
• Ferguson HE, Kulkarni A, Lehmann GM, et al. Electrophilic peroxisome proliferator-activated receptor-γ ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol. 2009;41(6):722–730. doi:10.1165/rcmb.2009-0006OC
   PubMed Web of Science ®Google Scholar
• Okada M, Yan SF, Pinsky DJ. Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J. 2002;16(14):1861–1868. doi:10.1096/fj.02-0503com
   PubMed Web of Science ®Google Scholar
• Sharma R, Kaundal RK, Sharma SS. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPARγ agonist in LPS-exposed guinea pigs. Pulm Pharmacol Ther. 2009;22(3):183–189. doi:10.1016/j.pupt.2008.11.011
   PubMed Web of Science ®Google Scholar
• Samah M, El-Aidy Ael R, Tawfik MK, Ewais MM. Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol. 2012;689(1–3):186–193. doi:10.1016/j.ejphar.2012.05.026
   PubMed Web of Science ®Google Scholar
• Elaidy SM, Essawy SS, Hussain MA, El-Kherbetawy MK, Hamed ER. Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(3):309–321. doi:10.1007/s00210-017-1459-z
   PubMed Web of Science ®Google Scholar
• Becker J, Delayre-Orthez C, Frossard N, Pons F. The peroxisome proliferator-activated receptor α agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung. Fundam Clin Pharmacol. 2012;26(3):340–346. doi:10.1111/j.1472-8206.2011.00935.x
   PubMed Web of Science ®Google Scholar
• Cui H, Xie N, Banerjee S, Ge J, Guo S, Liu G. Impairment of fatty acid oxidation in alveolar epithelial cells mediates acute lung injury. Am J Respir Cell Mol Biol. 2019;60(2):167–178. doi:10.1165/rcmb.2018-0152OC
   PubMed Web of Science ®Google Scholar
• Delayre-Orthez C, Becker J, Auwerx J, Frossard N, Pons F. Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-α agonist fenofibrate. Eur J Pharmacol. 2008;581(1–2):177–184.
   PubMed Web of Science ®Google Scholar
• Zhu Q, He G, Wang J, Wang Y, Chen W. Protective effects of fenofibrate against acute lung injury induced by intestinal ischemia/reperfusion in mice. Sci Rep. 2016;6:22044. doi:10.1038/srep22044
   PubMed Web of Science ®Google Scholar
• Stolarz AJ, Farris RA, Wiley CA, O’Brien CE, Price ET. Fenofibrate attenuates neutrophilic inflammation in airway epithelia: potential drug repurposing for cystic fibrosis. Clin Transl Sci. 2015;8(6):696–701. doi:10.1111/cts.12310
   PubMed Web of Science ®Google Scholar
• Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of peroxisome proliferator-activated receptor-α expression during lung inflammation. Pulm Pharmacol Ther. 2008;21(2):324–330. doi:10.1016/j.pupt.2007.08.001
   PubMed Web of Science ®Google Scholar
• Delayre-Orthez C, Becker J, Guenon I, et al. PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res. 2005;6(1):91. doi:10.1186/1465-9921-6-91
   PubMedGoogle Scholar
• Ke Q, Yang L, Cui Q, et al. Ciprofibrate attenuates airway remodeling in cigarette smoke-exposed rats. Respir Physiol Neurobiol. 2020;271:103290. doi:10.1016/j.resp.2019.103290
   PubMed Web of Science ®Google Scholar
• Reiterer G, Toborek M, Hennig B. Peroxisome proliferator activated receptors α and γ require zinc for their anti-inflammatory properties in porcine vascular endothelial cells. J Nutr. 2004;134(7):1711–1715. doi:10.1093/jn/134.7.1711
   PubMed Web of Science ®Google Scholar
• Schaefer MB, Pose A, Ott J, et al. Peroxisome proliferator-activated receptor-α reduces inflammation and vascular leakage in a murine model of acute lung injury. Eur Respir J. 2008;32(5):1344–1353. doi:10.1183/09031936.00035808
   PubMed Web of Science ®Google Scholar
• Yoo SH, Abdelmegeed MA, Song BJ. Activation of PPARα by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury. Biochem Biophys Res Commun. 2013;436(3):366–371. doi:10.1016/j.bbrc.2013.05.073
   PubMed Web of Science ®Google Scholar
• Yanagisawa J, Shiraishi T, Iwasaki A, et al. PPARα ligand WY14643 reduced acute rejection after rat lung transplantation with the upregulation of IL-4, IL-10 and TGFβ mRNA expression. J Heart Lung Transplant. 2009;28(11):1172–1179. doi:10.1016/j.healun.2009.06.016
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–2024. doi:10.1001/jama.2015.15629
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi:10.1136/bmj.b2376
   PubMed Web of Science ®Google Scholar
• Ajmera M, Shen C, Sambamoorthi U. Association between statin medications and COPD-specific outcomes: a real-world observational study. Drugs Real World Outcomes. 2017;4(1):9–19. doi:10.1007/s40801-016-0101-6
   PubMedGoogle Scholar
• Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med. 2013;126(7):598–606.e592. doi:10.1016/j.amjmed.2013.01.036
   Web of Science ®Google Scholar
• Lu Y, Chang R, Yao J, Xu X, Teng Y, Cheng N. Effectiveness of long-term using statins in COPD - a network meta-analysis. Respir Res. 2019;20(1):17. doi:10.1186/s12931-019-0984-3
   PubMedGoogle Scholar
• Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009;18(114):222–232. doi:10.1183/09059180.00005309
   PubMedGoogle Scholar
• Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J. 2009;85(1006):414–421. doi:10.1136/pgmj.2008.078477
   PubMed Web of Science ®Google Scholar
• Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013;26(2):212–217. doi:10.1016/j.pupt.2012.10.008
   PubMed Web of Science ®Google Scholar
• Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials. Drug Des Devel Ther. 2019;13:405–422. doi:10.2147/DDDT.S187690
   PubMed Web of Science ®Google Scholar
• Raymakers A, Sin DD, Sadatsafavi M, FitzGerald JM, Marra CA, Lynd LD. Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study. Respir Res. 2020;21(1):118. doi:10.1186/s12931-020-01344-w
   PubMed Web of Science ®Google Scholar
• Wu WT, Chen CY. Protective effect of statins on pulmonary hypertension in chronic obstructive pulmonary disease patients: a nationwide retrospective, matched cohort study. Sci Rep. 2020;10(1):3104. doi:10.1038/s41598-020-59828-0
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008;121(11):1002–1007.e1001. doi:10.1016/j.amjmed.2008.06.030
   Web of Science ®Google Scholar
• Troeman DP, Postma DF, van Werkhoven CH, Oosterheert JJ. The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect. 2013;67(2):93–101. doi:10.1016/j.jinf.2013.04.015
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ. The mevalonate pathway and innate immune hyper-responsiveness in the pathogenesis of COPD and lung cancer: potential for chemoprevention. Curr Mol Pharmacol. 2017;10(1):46–59. doi:10.2174/1874467209666160112130016
   PubMed Web of Science ®Google Scholar
• Singla S, Jacobson JR. Statins as a novel therapeutic strategy in acute lung injury. Pulm Circ. 2012;2(4):397–406. doi:10.4103/2045-8932.105028
   PubMedGoogle Scholar
• Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729–734. doi:10.1136/thx.2005.057976
   PubMed Web of Science ®Google Scholar
• Malekinejad H, Khoramjouy M, Hobbenaghi R, Amniattalab A. Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: a new indication for atorvastatin. Pestic Biochem Physiol. 2014;114:79–89. doi:10.1016/j.pestbp.2014.06.011
   PubMed Web of Science ®Google Scholar
• El-Achkar GA, Mrad MF, Mouawad CA, et al. Heme oxygenase-1-Dependent anti-inflammatory effects of atorvastatin in zymosan-injected subcutaneous air pouch in mice. PLoS One. 2019;14(5):e0216405. doi:10.1371/journal.pone.0216405
   PubMed Web of Science ®Google Scholar
• Zhu T, Zhang W, Wang DX, et al. Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor. Chin Med J (Engl). 2012;125(8):1457–1464.
   PubMed Web of Science ®Google Scholar
• Leite CF, Marangoni FA, Camargo EA, et al. Simvastatin attenuates neutrophil recruitment in one-lung ventilation model in rats. Acta Cir Bras. 2013;28(4):245–250. doi:10.1590/S0102-86502013000400003
   PubMed Web of Science ®Google Scholar
• Davis BB, Zeki AA, Bratt JM, et al. Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy. Eur Respir J. 2013;42(2):350–361. doi:10.1183/09031936.00042512
   PubMed Web of Science ®Google Scholar
• Zhang S, Rahman M, Zhang S, Qi Z, Herwald H, Thorlacius H. Simvastatin regulates CXC chemokine formation in streptococcal M1 protein-induced neutrophil infiltration in the lung. Am J Physiol Lung Cell Mol Physiol. 2011;300(6):L930–939. doi:10.1152/ajplung.00422.2010
   PubMed Web of Science ®Google Scholar
• Tulek B, Kiyan E, Kiyici A, Toy H, Bariskaner H, Suerdem M. Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats. Biol Res. 2012;45(4):345–350. doi:10.4067/S0716-97602012000400003
   PubMed Web of Science ®Google Scholar
• Müller HC, Hellwig K, Rosseau S, et al. Simvastatin attenuates ventilator-induced lung injury in mice. Crit Care. 2010;14(4):R143. doi:10.1186/cc9209
   PubMed Web of Science ®Google Scholar
• Hsu HH, Ko WJ, Hsu JY, et al. Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. Respir Res. 2009;10(1):32. doi:10.1186/1465-9921-10-32
   PubMedGoogle Scholar
• Li M, Liu Y, Shi H, et al. Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21WAF1. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(10):961–968. doi:10.1007/s00210-012-0768-5
   PubMed Web of Science ®Google Scholar
• Hsu M, Muchova L, Morioka I, Wong RJ, Schröder H, Stevenson DK. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun. 2006;343(3):738–744. doi:10.1016/j.bbrc.2006.03.036
   PubMed Web of Science ®Google Scholar
• Drummond GS, Baum J, Greenberg M, Lewis D, Abraham NG. HO-1 overexpression and underexpression: clinical implications. Arch Biochem Biophys. 2019;673:108073.
   PubMed Web of Science ®Google Scholar
• Pereira MLM, Marinho CRF, Epiphanio S. Could heme oxygenase-1 be a new target for therapeutic intervention in malaria-associated acute lung injury/acute respiratory distress syndrome? Front Cell Infect Microbiol. 2018;8:161. doi:10.3389/fcimb.2018.00161
   PubMed Web of Science ®Google Scholar
• Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med. 2005;171(6):606–615. doi:10.1164/rccm.200406-729OC
   PubMed Web of Science ®Google Scholar
• Xu JF, Washko GR, Nakahira K, et al. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med. 2012;185(5):547–556. doi:10.1164/rccm.201108-1574OC
   PubMed Web of Science ®Google Scholar
• Walsh A, Perrem L, Khashan AS, Henry MT, Ni Chroinin M. Statins versus placebo for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;7(7):Cd011959. doi:10.1002/14651858.CD011959.pub2
   Web of Science ®Google Scholar
• Bradbury P, Traini D, Ammit AJ, Young PM, Ong HX. Repurposing of statins via inhalation to treat lung inflammatory conditions. Adv Drug Deliv Rev. 2018;133:93–106. doi:10.1016/j.addr.2018.06.005
   PubMed Web of Science ®Google Scholar
• Chen T, Liu W, Chao X, et al. Salvianolic acid B attenuates brain damage and inflammation after traumatic brain injury in mice. Brain Res Bull. 2011;84(2):163–168. doi:10.1016/j.brainresbull.2010.11.015
   PubMed Web of Science ®Google Scholar
• Pan Y, Fu H, Kong Q, et al. Prevention of pulmonary fibrosis with salvianolic acid a by inducing fibroblast cell cycle arrest and promoting apoptosis. J Ethnopharmacol. 2014;155(3):1589–1596. doi:10.1016/j.jep.2014.07.049
   PubMed Web of Science ®Google Scholar
• Mu D, Luan Y, Wang L, et al. The combination of salvianolic acid A with latamoxef completely protects mice against lethal pneumonia caused by methicillin-resistant Staphylococcus aureus. Emerg Microbes Infect. 2020;9(1):169–179. doi:10.1080/22221751.2020.1711817
   PubMed Web of Science ®Google Scholar
• Zhao DH, Wu YJ, Liu ST, Liu RY. Salvianolic acid B attenuates lipopolysaccharide-induced acute lung injury in rats through inhibition of apoptosis, oxidative stress and inflammation. Exp Ther Med. 2017;14(1):759–764. doi:10.3892/etm.2017.4534
   PubMed Web of Science ®Google Scholar
• Zhang DF, Zhang J, Li R. Salvianolic acid B attenuates lung inflammation induced by cigarette smoke in mice. Eur J Pharmacol. 2015;761:174–179. doi:10.1016/j.ejphar.2015.05.003
   PubMed Web of Science ®Google Scholar
• Liu B, Cao B, Zhang D, et al. Salvianolic acid B protects against paraquat-induced pulmonary injury by mediating Nrf2/Nox4 redox balance and TGF-β1/Smad3 signaling. Toxicol Appl Pharmacol. 2016;309:111–120. doi:10.1016/j.taap.2016.08.004
   PubMed Web of Science ®Google Scholar
• Huang X, Zuo L, Lv Y, et al. Asiatic acid attenuates myocardial ischemia/reperfusion injury via Akt/GSK-3β/HIF-1α signaling in rat H9c2 cardiomyocytes. Molecules. 2016;21(9):1248. doi:10.3390/molecules21091248
   PubMed Web of Science ®Google Scholar
• Wei J, Huang Q, Huang R, et al. Asiatic acid from Potentilla chinensis attenuate ethanol-induced hepatic injury via suppression of oxidative stress and Kupffer cell activation. Biol Pharm Bull. 2013;36(12):1980–1989. doi:10.1248/bpb.b13-00634
   PubMed Web of Science ®Google Scholar
• Adtani PN, Narasimhan M, Punnoose AM, Kambalachenu HR. Antifibrotic effect of Centella asiatica Linn and asiatic acid on arecoline-induced fibrosis in human buccal fibroblasts. J Investig Clin Dent. 2017;8(2):e12208. doi:10.1111/jicd.12208
   Google Scholar
• Dong SH, Liu YW, Wei F, Tan HZ, Han ZD. Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (BLM) via suppressing pro-fibrotic and inflammatory signaling pathways. Biomed Pharmacother. 2017;89:1297–1309. doi:10.1016/j.biopha.2017.03.005
   PubMed Web of Science ®Google Scholar
• Xia X, Dai C, Yu H, et al. Asiatic acid prevents the development of interstitial lung disease in a hypochlorous acid-induced mouse model of scleroderma. Oncol Lett. 2018;15(6):8711–8716. doi:10.3892/ol.2018.8412
   PubMed Web of Science ®Google Scholar
• Jiang W, Li M, He F, et al. Protective effects of asiatic acid against spinal cord injury-induced acute lung injury in rats. Inflammation. 2016;39(6):1853–1861. doi:10.1007/s10753-016-0414-3
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang B, Li J, et al. Celastrol attenuates incision-induced inflammation and pain associated with inhibition of the NF-κB signalling pathway via SARM. Life Sci. 2018;205:136–144. doi:10.1016/j.lfs.2018.05.020
   PubMed Web of Science ®Google Scholar
• Yu X, Zhao Q, Zhang X, et al. Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. Oncotarget. 2017;8(40):67300–67314. doi:10.18632/oncotarget.18619
   PubMedGoogle Scholar
• Zhang X, Wang Y, Ge HY, et al. Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA. J Cell Physiol. 2018;233(10):6814–6824. doi:10.1002/jcp.26547
   PubMed Web of Science ®Google Scholar
• Shi K, Chen X, Xie B, et al. Celastrol alleviates chronic obstructive pulmonary disease by inhibiting cellular inflammation induced by cigarette smoke via the Ednrb/Kng1 signaling pathway. Front Pharmacol. 2018;9:1276. doi:10.3389/fphar.2018.01276
   PubMed Web of Science ®Google Scholar
• Liu J, Liu J, Wang H, Bai M. Protective effect of celastrol for burn-induced acute lung injury in rats. Int J Clin Exp Pathol. 2019;12(2):576–583.
   PubMed Web of Science ®Google Scholar
• Kim SC, Kang SH, Jeong SJ, Kim SH, Ko HS, Kim SH. Inhibition of c-Jun N-terminal kinase and nuclear factor κ B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells. Immunopharmacol Immunotoxicol. 2012;34(4):645–650. doi:10.3109/08923973.2011.648270
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Jia SS. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways. Biomed Pharmacother. 2016;83:1164–1174. doi:10.1016/j.biopha.2016.08.035
   PubMed Web of Science ®Google Scholar
• Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19(2):151–162. doi:10.1089/ars.2012.4901
   PubMed Web of Science ®Google Scholar
• Weseler AR, Geraets L, Moonen HJ, et al. Poly (ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes. J Nutr. 2009;139(5):952–957. doi:10.3945/jn.108.102756
   PubMed Web of Science ®Google Scholar
• Feng G, Jiang ZY, Sun B, Fu J, Li TZ. Fisetin alleviates lipopolysaccharide-induced acute lung injury via TLR4-mediated NF-κB signaling pathway in rats. Inflammation. 2016;39(1):148–157. doi:10.1007/s10753-015-0233-y
   PubMed Web of Science ®Google Scholar
• Huang W, Li ML, Xia MY, Shao JY. Fisetin-treatment alleviates airway inflammation through inhbition of MyD88/NF-κB signaling pathway. Int J Mol Med. 2018;42(1):208–218. doi:10.3892/ijmm.2018.3582
   PubMed Web of Science ®Google Scholar
• Wang X, Gong G, Yang W, Li Y, Jiang M, Li L. Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model. Environ Toxicol Pharmacol. 2013;36(2):288–295. doi:10.1016/j.etap.2013.04.004
   PubMed Web of Science ®Google Scholar
• Liu YN, Zha WJ, Ma Y, et al. Galangin attenuates airway remodelling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma. Sci Rep. 2015;5:11758. doi:10.1038/srep11758
   PubMed Web of Science ®Google Scholar
• Henry LJK, Ramar MK, Palanisamy S, Natesan S, Kandasamy R. Mechanistic investigation of PPARγ-facilitated anti-asthmatic effects of Galangin (Norizalpinin): insights from in silico and in vivo analyses. Biochem Biophys Res Commun. 2020;526(3):833–840. doi:10.1016/j.bbrc.2020.03.158
   PubMed Web of Science ®Google Scholar
• Somerset SM, Johannot L. Dietary flavonoid sources in Australian adults. Nutr Cancer. 2008;60(4):442–449. doi:10.1080/01635580802143836
   PubMed Web of Science ®Google Scholar
• Cheng X, Yang YL, Yang H, Wang YH, Du GH. Kaempferol alleviates LPS-induced neuroinflammation and BBB dysfunction in mice via inhibiting HMGB1 release and down-regulating TLR4/MyD88 pathway. Int Immunopharmacol. 2018;56:29–35. doi:10.1016/j.intimp.2018.01.002
   PubMed Web of Science ®Google Scholar
• Chen X, Qian J, Wang L, et al. Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress. Endocrine. 2018;60(1):83–94. doi:10.1007/s12020-018-1525-4
   PubMed Web of Science ®Google Scholar
• Zhang R, Ai X, Duan Y, et al. Kaempferol ameliorates H9N2 swine influenza virus-induced acute lung injury by inactivation of TLR4/MyD88-mediated NF-κB and MAPK signaling pathways. Biomed Pharmacother. 2017;89:660–672. doi:10.1016/j.biopha.2017.02.081
   PubMed Web of Science ®Google Scholar
• Kang DR, Belal SA, Choe HS, Shin DK, Shim KS. Effect of kaempferol on cyclooxygenase 2 (Cox2) and cytosolic phospholipase A2 (cPLA2) protein expression in BALB/c mice. Iran J Allergy Asthma Immunol. 2018;17(5):428–435. doi:10.18502/ijaai.v17i5.301
   PubMed Web of Science ®Google Scholar
• Chen X, Yang X, Liu T, et al. Kaempferol regulates MAPKs and NF-κB signaling pathways to attenuate LPS-induced acute lung injury in mice. Int Immunopharmacol. 2012;14(2):209–216. doi:10.1016/j.intimp.2012.07.007
   PubMed Web of Science ®Google Scholar
• Sun Z, Li Q, Hou R, et al. Kaempferol-3-O-glucorhamnoside inhibits inflammatory responses via MAPK and NF-κB pathways in vitro and in vivo. Toxicol Appl Pharmacol. 2019;364:22–28. doi:10.1016/j.taap.2018.12.008
   PubMed Web of Science ®Google Scholar
• Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8(7):634–646. doi:10.2174/156800908786241050
   PubMed Web of Science ®Google Scholar
• Aziz N, Kim MY, Cho JY. Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018;225:342–358. doi:10.1016/j.jep.2018.05.019
   PubMed Web of Science ®Google Scholar
• Xiong J, Wang K, Yuan C, et al. Luteolin protects mice from severe acute pancreatitis by exerting HO-1-mediated anti-inflammatory and antioxidant effects. Int J Mol Med. 2017;39(1):113–125. doi:10.3892/ijmm.2016.2809
   PubMed Web of Science ®Google Scholar
• Liu X, Meng J. Luteolin alleviates LPS-induced bronchopneumonia injury in vitro and in vivo by down-regulating microRNA-132 expression. Biomed Pharmacother. 2018;106:1641–1649. doi:10.1016/j.biopha.2018.07.094
   PubMed Web of Science ®Google Scholar
• Chen CY, Peng WH, Wu LC, Wu CC, Hsu SL. Luteolin ameliorates experimental lung fibrosis both in vivo and in vitro: implications for therapy of lung fibrosis. J Agric Food Chem. 2010;58(22):11653–11661. doi:10.1021/jf1031668
   PubMed Web of Science ®Google Scholar
• Liu B, Yu H, Baiyun R, et al. Protective effects of dietary luteolin against mercuric chloride-induced lung injury in mice: involvement of AKT/Nrf2 and NF-κB pathways. Food Chem Toxicol. 2018;113:296–302. doi:10.1016/j.fct.2018.02.003
   PubMed Web of Science ®Google Scholar
• Hsuan CF, Hsu HF, Tseng WK, et al. Glossogyne tenuifolia extract inhibits TNF-α-induced expression of adhesion molecules in human umbilical vein endothelial cells via blocking the NF-kB signaling pathway. Molecules. 2015;20(9):16908–16923. doi:10.3390/molecules200916908
   PubMed Web of Science ®Google Scholar
• Bian D, Liu M, Li Y, Xia Y, Gong Z, Dai Y. Madecassoside, a triterpenoid saponin isolated from Centella asiatica herbs, protects endothelial cells against oxidative stress. J Biochem Mol Toxicol. 2012;26(10):399–406. doi:10.1002/jbt.21434
   PubMed Web of Science ®Google Scholar
• Luo Y, Yang YP, Liu J, et al. Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res. 2014;1565:37–47. doi:10.1016/j.brainres.2014.04.008
   PubMed Web of Science ®Google Scholar
• Bian GX, Li GG, Yang Y, et al. Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat. Biol Pharm Bull. 2008;31(3):458–463. doi:10.1248/bpb.31.458
   PubMed Web of Science ®Google Scholar
• Lu GX, Bian DF, Ji Y, et al. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen deposition. Phytother Res. 2014;28(8):1224–1231. doi:10.1002/ptr.5120
   PubMed Web of Science ®Google Scholar
• Pollier J, Goossens A. Oleanolic acid. Phytochemistry. 2012;77:10–15. doi:10.1016/j.phytochem.2011.12.022
   PubMed Web of Science ®Google Scholar
• Ayeleso TB, Matumba MG, Mukwevho E. Oleanolic acid and its derivatives: biological activities and therapeutic potential in chronic diseases. Molecules. 2017;22(11). doi:10.3390/molecules22111915
   PubMed Web of Science ®Google Scholar
• Zhang DH, Yang L, Cohn L, et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity. 1999;11(4):473–482. doi:10.1016/S1074-7613(00)80122-3
   PubMed Web of Science ®Google Scholar
• Kim SH, Hong JH, Lee YC. Oleanolic acid suppresses ovalbumin-induced airway inflammation and Th2-mediated allergic asthma by modulating the transcription factors T-bet, GATA-3, RORγt and Foxp3 in asthmatic mice. Int Immunopharmacol. 2014;18(2):311–324. doi:10.1016/j.intimp.2013.12.009
   PubMed Web of Science ®Google Scholar
• Santos RS, Silva PL, Oliveira GP, et al. Effects of oleanolic acid on pulmonary morphofunctional and biochemical variables in experimental acute lung injury. Respir Physiol Neurobiol. 2011;179(2–3):129–136. doi:10.1016/j.resp.2011.07.008
   PubMed Web of Science ®Google Scholar
• Santos RS, Silva PL, de Oliveira GP, et al. Oleanolic acid improves pulmonary morphofunctional parameters in experimental sepsis by modulating oxidative and apoptotic processes. Respir Physiol Neurobiol. 2013;189(3):484–490. doi:10.1016/j.resp.2013.08.019
   PubMed Web of Science ®Google Scholar
• Kim W, Lim D, Kim J. p-Coumaric acid, a major active compound of bambusae caulis in taeniam, suppresses cigarette smoke-induced pulmonary inflammation. Am J Chin Med. 2018;46(2):407–421. doi:10.1142/S0192415X18500209
   PubMed Web of Science ®Google Scholar
• Lee CH, Wu SL, Chen JC, et al. Eriobotrya japonica leaf and its triterpenes inhibited lipopolysaccharide-induced cytokines and inducible enzyme production via the nuclear factor-κB signaling pathway in lung epithelial cells. Am J Chin Med. 2008;36(6):1185–1198. doi:10.1142/S0192415X0800651X
   PubMed Web of Science ®Google Scholar
• Peng XP, Li XH, Li Y, Huang XT, Luo ZQ. The protective effect of oleanolic acid on NMDA-induced MLE-12 cells apoptosis and lung injury in mice by activating SIRT1 and reducing NF-κB acetylation. Int Immunopharmacol. 2019;70:520–529. doi:10.1016/j.intimp.2019.03.018
   PubMed Web of Science ®Google Scholar
• Thimmulappa RK, Fuchs RJ, Malhotra D, et al. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid Redox Signal. 2007;9(11):1963–1970. doi:10.1089/ars.2007.1745
   PubMed Web of Science ®Google Scholar
• To C, Ringelberg CS, Royce DB, et al. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis. 2015;36(7):769–781. doi:10.1093/carcin/bgv061
   PubMed Web of Science ®Google Scholar
• Chen T, Mou Y, Tan J, et al. The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2015;25(1):55–64. doi:10.1016/j.intimp.2015.01.011
   PubMed Web of Science ®Google Scholar
• Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB. The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol. 2009;297(5):L828–836. doi:10.1152/ajplung.00171.2009
   PubMed Web of Science ®Google Scholar
• Kulkarni AA, Thatcher TH, Hsiao HM, et al. The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis. PLoS One. 2013;8(5):e63798. doi:10.1371/journal.pone.0063798
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhang CY, Ma YQ, He ZX, Zhe H, Zhou SF. Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice. Drug Des Devel Ther. 2015;9:3163–3178. doi:10.2147/DDDT.S80958
   PubMed Web of Science ®Google Scholar
• Wu SJ, Tam KW, Tsai YH, Chang CC, Chao JC. Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats. Am J Chin Med. 2010;38(1):99–111. doi:10.1142/S0192415X10007695
   PubMed Web of Science ®Google Scholar
• Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry. 2007;68(6):732–766. doi:10.1016/j.phytochem.2006.11.029
   PubMed Web of Science ®Google Scholar
• Carvalho PR, Silva DH, Bolzani VS, Furlan M. Antioxidant quinonemethide triterpenes from Salacia campestris. Chem Biodivers. 2005;2(3):367–372. doi:10.1002/cbdv.200590016
   PubMed Web of Science ®Google Scholar
• Li JJ, Yan YY, Sun HM, et al. Anti-cancer effects of pristimerin and the mechanisms: a critical review. Front Pharmacol. 2019;10:746. doi:10.3389/fphar.2019.00746
   PubMed Web of Science ®Google Scholar
• Zhao Q, Liu Y, Zhong J, et al. Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo. Cell Death Discov. 2019;5:125. doi:10.1038/s41420-019-0208-0
   PubMed Web of Science ®Google Scholar
• Yang CC, Hsiao LD, Tseng HC, Kuo CM, Yang CM. Pristimerin Inhibits MMP-9 expression and cell migration through attenuating NOX/ROS-dependent NF-κB activation in rat brain astrocytes challenged with LPS. J Inflamm Res. 2020;13:325–341. doi:10.2147/JIR.S252659
   PubMed Web of Science ®Google Scholar
• Shaaban AA, El-Kashef DH, Hamed MF, El-Agamy DS. Protective effect of pristimerin against LPS-induced acute lung injury in mice. Int Immunopharmacol. 2018;59:31–39. doi:10.1016/j.intimp.2018.03.033
   PubMed Web of Science ®Google Scholar